DPYD Monoclonal Antibody
- Size: 100ul
- Application: WB, IHC-P
- Reactivity: Human
- Predicted Reactivity:
-
Datasheet
Tech Support
IMAGES
Paraformaldehyde-fixed, paraffin embedded Human liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with DPYD Monoclonal Antibody, Unconjugated (bsm-54740R) at 1:200 for 30 minutes at room temperature, DAB staining.
PRODUCT DETAILS
SPECIFICATIONS |
|
|---|---|
|
PRODUCT NAME |
DPYD Monoclonal Antibody |
|
CONJUGATION |
Unconjugated |
|
HOST |
Rabbit |
| SOURCE |
Synthetic peptide corresponding to C-terminal Human DPYD. |
| IMMUNOGEN RANGE |
|
| CLONALITY |
Monoclonal |
| ISOTYPE |
IgG |
| CONCENTRATION |
1ug/ul |
| PURIFICATION |
Purified by Protein A. |
| STORAGE BUFFER |
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. |
| STORAGE CONDITION |
Store at -20°C for 12 months.. |
TARGET |
|
|---|---|
| GENE ID |
|
| SUBCELLULAR LOCATION |
Cytoplasm |
| SYNONYMS |
DHP antibody, DHPDHase antibody, Dihydropyrimidine dehydrogenase [NADP(+)] antibody, Dihydropyrimidine dehydrogenase [NADP+] antibody, Dihydropyrimidine dehydrogenase antibody, Dihydrothymine dehydrogenase antibody, Dihydrouracil dehydrogenase antibody, DPD antibody, DPYD antibody, DPYD_HUMAN antibody, MGC132008 antibody, MGC70799 antibody, OTTHUMP00000058954 antibody |
| BACKGROUND |
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU. Involvement in disease: Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma. |
| APPLICATION DILUTION |
WB(1:300-1000), IHC-P(1:200-400) |